Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAFV600 Mutation

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Targeted oncology

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11523-016-0443-8PMID 27246822
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic efficacy and safety of combined BRAF and MEK inhibition in patients with malignant melanoma: a meta-analysis

  2017cited by this paper
• NRAS-mutant melanoma: current challenges and future prospect

  2017cited by this paper
• Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

  2016cited by this paper
• Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial

  2016cited by this paper
• Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy

  2016cited by this paper
• Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

  2016cited by this paper
• Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

  2015cited by this paper
• Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?

  2015cited by this paper
• The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma

  2015cited by this paper
• Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.

  2015influential reference
• Combination therapy of melanoma using kinase inhibitors

  2015cited by this paper
• Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

  2015influential reference
• Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.

  2015cited by this paper
• Improved overall survival in melanoma with combined dabrafenib and trametinib.

  2015influential reference
• Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastatic melanoma: Exploration of clinical and molecular predictors of response.

  2015cited by this paper
• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

  2015cited by this paper
• Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma

  2014cited by this paper
• The Metabolic Drug-Drug Interaction Profile of Dabrafenib: In Vitro Investigations and Quantitative Extrapolation of the P450-Mediated DDI Risk

  2014cited by this paper
• Current and Future Roles of Targeted Therapy and Immunotherapy in Advanced Melanoma

  2014influential reference
• Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

  2014cited by this paper
• Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

  2014cited by this paper
• Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers

  2014cited by this paper
• Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites

  2014cited by this paper
• Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

  2014cited by this paper
• Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours.

  2014cited by this paper
• Melanoma: Molecular Pathogenesis and Therapeutic Management.

  2014cited by this paper
• Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

  2014cited by this paper
• Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program

  2014cited by this paper
• LBA4_PRCOMBI-V: A RANDOMISED, OPEN-LABEL, PHASE III STUDY COMPARING THE COMBINATION OF DABRAFENIB (D) AND TRAMETINIB (T) WITH VEMURAFENIB (V) AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH UNRESECTABLE OR METASTATIC BRAF V600E/K MUTATION-POSITIVE CUTANEOUS MELANOMA

  2014cited by this paper
• Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

  2014cited by this paper
• Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

  2014cited by this paper
• Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

  2013cited by this paper
• Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

  2013cited by this paper
• Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

  2013cited by this paper
• Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

  2013influential reference
• Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation‐Positive Solid Tumors

  2013cited by this paper
• Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors.

  2013cited by this paper
• Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation

  2013influential reference
• Evaluation of the Effects of Food on the Single‐Dose Pharmacokinetics of Trametinib, a First‐in‐Class MEK Inhibitor, in Patients with Cancer

  2013cited by this paper
• Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM).

  2013cited by this paper
• Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

  2012cited by this paper
• Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

  2012cited by this paper
• Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2012cited by this paper
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.

  2012cited by this paper
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

  2012cited by this paper
• Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2

  2012cited by this paper
• RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

  2012cited by this paper
• Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

  2012cited by this paper
• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

  2011cited by this paper
• Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

  2010cited by this paper

• Co-administration of phytochemicals and anti-melanoma drugs: Mechanisms, metastasis prevention, and regulatory challenges

  2026cites this paper
• Iron, copper and disulfide dysregulation: molecular crossroads of metabolic cell death in melanoma progression

  2025cites this paper
• Structural elucidation, Hirshfeld surface, DFT, molecular docking and molecular dynamics studies of a novel thiazole derivative as anti-cancer drug

  2024cites this paper
• Rational design, synthesis and anticancer screening of 1,2,4-oxadiazole incorporated thieno[2,3-d]thiazole-isoxazole-pyridine derivatives

  2024cites this paper
• A synergistic investigation of azo-thiazole derivatives incorporating thiazole moieties: a comprehensive exploration of their synthesis, characterization, computational insights, solvatochromism, and multimodal biological activity assessment

  2023cites this paper
• Biomineralized Polydopamine Nanoparticle-Based Sodium Alginate Hydrogels for Delivery of Anti-serine/Threonine Protein Kinase B-Rapidly Accelerated Fibrosarcoma siRNA for Metastatic Melanoma Therapy.

  2023cites this paper
• Hyperforin Elicits Cytostatic/Cytotoxic Activity in Human Melanoma Cell Lines, Inhibiting Pro-Survival NF-κB, STAT3, AP1 Transcription Factors and the Expression of Functional Proteins Involved in Mitochondrial and Cytosolic Metabolism

  2023cites this paper
• Synthesis, Molecular Docking and Antiproliferative Activity Studies of a Thiazole‐Based Compound Linked to Hydrazone Moiety

  2022cites this paper
• DNA Methylation-Specific Analysis of G Protein-Coupled Receptor-Related Genes in Pan-Cancer

  2022cites this paper
• Molecular modeling and docking studies of new antimicrobial antipyrine-thiazole hybrids

  2022cites this paper
• Treatment of BRAF-Mutated Metastatic Melanoma: Immunotherapy or Target Therapy?

  2021cites this paper
• Structure-Based and Knowledge-Informed Design of B-Raf Inhibitors Devoid of Deleterious PXR Binding.

  2021cites this paper
• Recent Trends in rationally designed molecules as kinase inhibitors.

  2021cites this paper
• The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers

  2021cites this paper
• Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma

  2021cites this paper
• Engineering Cell Membrane-Based Nanovesicles for Melanoma Tumor Treatment.

  2021cites this paper
• Design, synthesis and anticancer evaluation of chalcone based thieno[2,3-d]thiazoles as anticancer agents

  2021cites this paper
• The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X Receptor

  2020cites this paper
• Efficacy and safety of dabrafenib–trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF‐V600 mutation: A systematic review and network meta‐analysis

  2020cites this paper
• Discovery of thiazole-based-chalcones and 4-hetarylthiazoles as potent anticancer agents: Synthesis, docking study and anticancer activity.

  2020cites this paper
• Trametinib potentiates TRAIL‐induced apoptosis via FBW7‐dependent Mcl‐1 degradation in colorectal cancer cells

  2020cites this paper
• TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel

  2020cites this paper
• Aspirin Induces Mitochondrial Ca2+ Remodeling in Tumor Cells via ROS‒Depolarization‒Voltage-Gated Ca2+ Entry

  2020cites this paper
• Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable or metastatic melanoma with BRAF V600 mutation: a systematic review and network meta-analysis.

  2020cites this paper
• Synthesis and antiproliferative activity studies of new functionalized pyridine linked thiazole derivatives

  2020cites this paper
• Vemurafenib resistant melanoma cells acquire mesenchymal stem cell-like properties

  2019influential citation
• BRAF-Mutant Melanoma

  2019cites this paper
• Phenformin as an Anticancer Agent: Challenges and Prospects

  2019cites this paper
• Dynamics of neutrophil and C‐reactive protein reflect the clinical course of pyrexia during combination therapy with dabrafenib and trametinib

  2019cites this paper
• Neue Arzneimittel 2018

  2019cites this paper
• Mechanisms of Resistance to Kinase Inhibitors and Strategies to Prevent the Development of Drug Resistance

  2018cites this paper
• Mek1Y130C mice recapitulate aspects of human cardio-facio-cutaneous syndrome

  2018cites this paper
• Systematic review and meta‐analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma

  2018cites this paper
• Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines

  2018cites this paper
• International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases

  2017cites this paper
• Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Induces Autophagic Protein Cleavage in Melanoma Cells

  2017cites this paper
• NRAS-mutant melanoma: current challenges and future prospect

  2017influential citation
• In Vitro Antiproliferative Activity of Extracts of Carlina acaulis subsp. caulescens and Carlina acanthifolia subsp. utzka

  2017cites this paper
• Therapeutic efficacy and safety of combined BRAF and MEK inhibition in patients with malignant melanoma: a meta-analysis

  2017cites this paper
• NRAS -mutant melanoma: current challenges and future prospect

  2017influential citation
• Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation.

  2017cites this paper
• Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches

  2017cites this paper